221 related articles for article (PubMed ID: 18070710)
1. Role of genetics in prognostication in myeloma.
Avet-Loiseau H
Best Pract Res Clin Haematol; 2007 Dec; 20(4):625-35. PubMed ID: 18070710
[TBL] [Abstract][Full Text] [Related]
2. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
[TBL] [Abstract][Full Text] [Related]
3. [Genetic markers as prognostic factors in multiple myeloma].
Conte L G; Braggio E; Figueroa G; Fonseca R
Rev Med Chil; 2009 Apr; 137(4):552-8. PubMed ID: 19623423
[TBL] [Abstract][Full Text] [Related]
4. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
[TBL] [Abstract][Full Text] [Related]
5. Novel chromosomal translocations in multiple myeloma: t(13;16)(q14;q24) and t(1;15)(q10;q26).
Akalin I; Kutlay NY; Ilhan O; Tukun A
Int J Lab Hematol; 2007 Jun; 29(3):215-20. PubMed ID: 17474900
[TBL] [Abstract][Full Text] [Related]
6. Genetics of multiple myeloma.
Higgins MJ; Fonseca R
Best Pract Res Clin Haematol; 2005; 18(4):525-36. PubMed ID: 16026735
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.
Cook JR; Hartke M; Pettay J; Tubbs RR
J Mol Diagn; 2006 Sep; 8(4):459-65. PubMed ID: 16931586
[TBL] [Abstract][Full Text] [Related]
8. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
[TBL] [Abstract][Full Text] [Related]
9. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics.
Bink K; Haralambieva E; Kremer M; Ott G; Beham-Schmid C; de Leval L; Peh SC; Laeng HR; Jütting U; Hutzler P; Quintanilla-Martinez L; Fend F
Haematologica; 2008 Apr; 93(4):623-6. PubMed ID: 18326524
[TBL] [Abstract][Full Text] [Related]
10. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Shaughnessy JD; Haessler J; van Rhee F; Anaissie E; Pineda-Roman M; Cottler-Fox M; Hollmig K; Zangari M; Mohiuddin A; Alsayed Y; Grazziutti M; Epstein J; Crowley J; Barlogie B
Br J Haematol; 2007 Jun; 137(6):530-6. PubMed ID: 17489983
[TBL] [Abstract][Full Text] [Related]
11. Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.
Sáez B; Martín-Subero JI; Odero MD; Prosper F; Cigudosa JC; Schoch R; Calasanz MJ; Siebert R
Oncol Rep; 2007 Nov; 18(5):1099-106. PubMed ID: 17914559
[TBL] [Abstract][Full Text] [Related]
12. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.
Hervé AL; Florence M; Philippe M; Michel A; Thierry F; Kenneth A; Jean-Luc H; Nikhil M; Stéphane M
J Clin Oncol; 2011 May; 29(14):1893-7. PubMed ID: 21482986
[TBL] [Abstract][Full Text] [Related]
13. [Study on molecular cytogenetic abnormalities in multiple myeloma].
Liu SY; Li JY; Chen LJ; Huang JW; Pan JL; Qiu HR; Shen YF; Xu W; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):223-6. PubMed ID: 17877196
[TBL] [Abstract][Full Text] [Related]
14. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor.
Panani AD; Ferti AD; Papaxoinis C; Raptis SA; Roussos Ch
Anticancer Res; 2004; 24(6):4141-6. PubMed ID: 15736465
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 1 abnormalities in multiple myeloma.
Marzin Y; Jamet D; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
Anticancer Res; 2006; 26(2A):953-9. PubMed ID: 16619492
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
[TBL] [Abstract][Full Text] [Related]
18. [Frequency and prognostic value of chromosome abnormalities in multiple myeloma].
Kurahashi S; Sawamoto A; Sugimoto T; Narimatsu H; Iwasaki T; Adachi T; Suzuki H; Hayakawa F; Sugiura I
Rinsho Ketsueki; 2007 Nov; 48(11):1455-61. PubMed ID: 18080502
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis.
Cavazzini F; Hernandez JA; Gozzetti A; Russo Rossi A; De Angeli C; Tiseo R; Bardi A; Tammiso E; Crupi R; Lenoci MP; Forconi F; Lauria F; Marasca R; Maffei R; Torelli G; Gonzalez M; Martin-Jimenez P; Maria Hernandez J; Rigolin GM; Cuneo A
Br J Haematol; 2008 Aug; 142(4):529-37. PubMed ID: 18547320
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic and molecular basis of multiple myeloma].
Taniwaki M; Matsumoto Y
Nihon Rinsho; 2007 Dec; 65(12):2179-86. PubMed ID: 18069258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
